Akèy › Myelom Miltip › Arizona › Phoenix
Etid klinik pou Myelom Miltip nan Phoenix, AZ
16 etid pou Myelom Miltip ap chèche patisipan nan sit nan ak bò kote Phoenix (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Ap rekriteFaz 3
- Mayo Clinic 1, Phoenix
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Ap rekriteFaz 3
- Mayo Clinic Phoenix, Phoenix
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
Ap rekriteFaz 3
- Mayo Clinic Phoenix, Mayo Clinic Building, Phoenix
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Ap rekriteFaz 4
- Mayo Clinic Cancer Center-Scottsdale, Phoenix
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Ap rekriteFaz 2
- Cancer Treatment Centers of America-Phoenix, Phoenix
Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
Ap rekriteFaz 1
- Mayo Clinic Hospital in Arizona, Phoenix
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
Ap rekriteFaz 1
- Mayo Clinic Arizona, Phoenix
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Ap rekriteFaz 3
- Cancer Center at Saint Joseph's, Phoenix
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Ap rekriteFaz 1/2
- Research Site, Phoenix
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Ap rekriteFaz 3
- Research Site, Phoenix
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Ap rekriteFaz 2
- Mayo Clinic - Arizona, Phoenix
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Ap rekriteFaz 1
- Mayo Clinic in Arizona - Phoenix, Phoenix
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
Ap rekriteFaz 1
- Mayo Clinic Arizona /ID# 251405, Phoenix
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Ap rekriteFaz 3
- Cancer Center at Saint Joseph's, Phoenix
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Ap rekriteFaz 3
- Banner University Medical Center Tucson, University of Arizona, Phoenix
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
Ap rekriteFaz 3
- GSK Investigational Site, Phoenix
Etid Myelom Miltip nan lòt vil
- New York City, NY60 etid
- Boston, MA42 etid
- Atlanta, GA41 etid
- Houston, TX38 etid
- Durham, NC37 etid
- Nashville, TN32 etid
- Denver, CO27 etid
- Rochester, MN24 etid
- St. Louis, MO24 etid
- Columbus, OH24 etid
- Baldwin Park, CA23 etid
- Chicago, IL22 etid
Lòt etid nan Phoenix
- Kansè nan tete25 etid
- Kansè kolorektal25 etid
- Obèsite22 etid
- Kansè Poumon ki pa ti selil20 etid
- Kansè Metastatik20 etid
- Ensifizyans kadyak18 etid
- Kansè pwostat17 etid
- Kansè (tout kalite)17 etid
- Kansè pankreyas16 etid
- Maladi kadyovaskilè16 etid
- Maladi Alzheimer15 etid
- Sipwa15 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.